613 related articles for article (PubMed ID: 34069461)
1. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.
Messeha SS; Zarmouh NO; Soliman KFA
Nutrients; 2021 May; 13(5):. PubMed ID: 34069461
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.
Chen L; Xiong Y; Li J; Zheng X; Zhou Q; Turner A; Wu C; Lu B; Jiang J
Cell Physiol Biochem; 2017; 42(6):2267-2280. PubMed ID: 28848143
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
6. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
7. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
8. Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells.
Wudtiwai B; Kodchakorn K; Shwe TH; Pothacharoen P; Phitak T; Suninthaboonrana R; Kongtawelert P
Int Immunopharmacol; 2023 May; 118():109988. PubMed ID: 36933493
[TBL] [Abstract][Full Text] [Related]
9. Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-β as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event.
Turini S; Bergandi L; Gazzano E; Prato M; Aldieri E
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609805
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
Tsutsumi S; Saeki H; Nakashima Y; Ito S; Oki E; Morita M; Oda Y; Okano S; Maehara Y
Cancer Sci; 2017 Jun; 108(6):1119-1127. PubMed ID: 28294486
[TBL] [Abstract][Full Text] [Related]
11. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition.
Secinti IE; Ozgur T; Dede I
Am J Clin Pathol; 2022 Oct; 158(4):506-515. PubMed ID: 35938631
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype.
Sahoo S; Nayak SP; Hari K; Purkait P; Mandal S; Kishore A; Levine H; Jolly MK
Front Immunol; 2021; 12():797261. PubMed ID: 34975907
[TBL] [Abstract][Full Text] [Related]
15. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
[TBL] [Abstract][Full Text] [Related]
16. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer.
Antony GR; Littleflower AB; Parambil ST; Subhadradevi L
Med Oncol; 2023 Feb; 40(4):108. PubMed ID: 36842157
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.
Funaki S; Shintani Y; Fukui E; Yamamoto Y; Kanzaki R; Ose N; Kanou T; Minami M; Mori E; Okumura M
Cancer Med; 2019 Jan; 8(1):216-226. PubMed ID: 30600651
[TBL] [Abstract][Full Text] [Related]
20. Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.
González-Martínez S; Pérez-Mies B; Pizarro D; Caniego-Casas T; Cortés J; Palacios J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
